Reconciling Antimicrobial Susceptibility Testing and Clinical Response in Antimicrobial Treatment of Chronic Cystic Fibrosis Lung Infections

Median cystic fibrosis (CF) survival has increased dramatically over time due to several factors, including greater availability and use of antimicrobial therapies. During the progression of CF lung disease, however, the emergence of multidrug antimicrobial resistance can limit treatment effectivene...

Full description

Saved in:
Bibliographic Details
Published in:Clinical infectious diseases 2019-10, Vol.69 (10), p.1812-1816
Main Authors: Waters, Valerie J, Kidd, Timothy J, Canton, Rafael, Ekkelenkamp, Miquel B, Johansen, Helle Krogh, LiPuma, John J, Bell, Scott C, Elborn, J Stuart, Flume, Patrick A, VanDevanter, Donald R, Gilligan, Peter
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c323t-a35b490a74987eb3894aa5607c86ada798fefe701e10fd8f67bb8c34499ca8a13
cites cdi_FETCH-LOGICAL-c323t-a35b490a74987eb3894aa5607c86ada798fefe701e10fd8f67bb8c34499ca8a13
container_end_page 1816
container_issue 10
container_start_page 1812
container_title Clinical infectious diseases
container_volume 69
creator Waters, Valerie J
Kidd, Timothy J
Canton, Rafael
Ekkelenkamp, Miquel B
Johansen, Helle Krogh
LiPuma, John J
Bell, Scott C
Elborn, J Stuart
Flume, Patrick A
VanDevanter, Donald R
Gilligan, Peter
description Median cystic fibrosis (CF) survival has increased dramatically over time due to several factors, including greater availability and use of antimicrobial therapies. During the progression of CF lung disease, however, the emergence of multidrug antimicrobial resistance can limit treatment effectiveness, threatening patient longevity. Current planktonic-based antimicrobial susceptibility testing lacks the ability to predict clinical response to antimicrobial treatment of chronic CF lung infections. There are numerous reasons for these limitations including bacterial phenotypic and genotypic diversity, polymicrobial interactions, and impaired antibiotic efficacy within the CF lung environment. The parallels to other chronic diseases such as non-CF bronchiectasis are discussed as well as research priorities for moving forward.
doi_str_mv 10.1093/cid/ciz364
format article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1093_cid_ciz364</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>31056660</sourcerecordid><originalsourceid>FETCH-LOGICAL-c323t-a35b490a74987eb3894aa5607c86ada798fefe701e10fd8f67bb8c34499ca8a13</originalsourceid><addsrcrecordid>eNpdkEFLAzEQhYMoVqsXf4DkLKwmJptNjmWxWigItZ6XJDvRSDe7bNJD_Q3-aFOqHjwMM_C-9xgeQleU3FKi2J31bZ5PJvgROqMlqwpRKnqcb1LKgksmJ-g8xg9CKJWkPEUTlhUhBDlDXyuwfbB-48MbnoXkO2_H3ni9wS_baGFI3mQx7fAaYtpDOrS4zri3mVlBHPoQAfvwz70eQacOQsK9w_X72GcDrnc5w-K5N2MffcTLbQ5cBAc2-RxzgU6c3kS4_NlT9Dp_WNdPxfL5cVHPloVl9ywVmpWGK6IrrmQFhknFtS4FqawUutWVkg4cVIQCJa6VTlTGSMs4V8pqqSmboptDbn42xhFcM4y-0-OuoaTZV9rkSptDpRm-PsDD1nTQ_qG_HbJvAD12ig</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Reconciling Antimicrobial Susceptibility Testing and Clinical Response in Antimicrobial Treatment of Chronic Cystic Fibrosis Lung Infections</title><source>Oxford Journals Online</source><creator>Waters, Valerie J ; Kidd, Timothy J ; Canton, Rafael ; Ekkelenkamp, Miquel B ; Johansen, Helle Krogh ; LiPuma, John J ; Bell, Scott C ; Elborn, J Stuart ; Flume, Patrick A ; VanDevanter, Donald R ; Gilligan, Peter</creator><creatorcontrib>Waters, Valerie J ; Kidd, Timothy J ; Canton, Rafael ; Ekkelenkamp, Miquel B ; Johansen, Helle Krogh ; LiPuma, John J ; Bell, Scott C ; Elborn, J Stuart ; Flume, Patrick A ; VanDevanter, Donald R ; Gilligan, Peter ; Antimicrobial Resistance International Working Group in Cystic Fibrosis ; Antimicrobial Resistance International Working Group in Cystic Fibrosis</creatorcontrib><description>Median cystic fibrosis (CF) survival has increased dramatically over time due to several factors, including greater availability and use of antimicrobial therapies. During the progression of CF lung disease, however, the emergence of multidrug antimicrobial resistance can limit treatment effectiveness, threatening patient longevity. Current planktonic-based antimicrobial susceptibility testing lacks the ability to predict clinical response to antimicrobial treatment of chronic CF lung infections. There are numerous reasons for these limitations including bacterial phenotypic and genotypic diversity, polymicrobial interactions, and impaired antibiotic efficacy within the CF lung environment. The parallels to other chronic diseases such as non-CF bronchiectasis are discussed as well as research priorities for moving forward.</description><identifier>ISSN: 1058-4838</identifier><identifier>EISSN: 1537-6591</identifier><identifier>DOI: 10.1093/cid/ciz364</identifier><identifier>PMID: 31056660</identifier><language>eng</language><publisher>United States</publisher><ispartof>Clinical infectious diseases, 2019-10, Vol.69 (10), p.1812-1816</ispartof><rights>The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c323t-a35b490a74987eb3894aa5607c86ada798fefe701e10fd8f67bb8c34499ca8a13</citedby><cites>FETCH-LOGICAL-c323t-a35b490a74987eb3894aa5607c86ada798fefe701e10fd8f67bb8c34499ca8a13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31056660$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Waters, Valerie J</creatorcontrib><creatorcontrib>Kidd, Timothy J</creatorcontrib><creatorcontrib>Canton, Rafael</creatorcontrib><creatorcontrib>Ekkelenkamp, Miquel B</creatorcontrib><creatorcontrib>Johansen, Helle Krogh</creatorcontrib><creatorcontrib>LiPuma, John J</creatorcontrib><creatorcontrib>Bell, Scott C</creatorcontrib><creatorcontrib>Elborn, J Stuart</creatorcontrib><creatorcontrib>Flume, Patrick A</creatorcontrib><creatorcontrib>VanDevanter, Donald R</creatorcontrib><creatorcontrib>Gilligan, Peter</creatorcontrib><creatorcontrib>Antimicrobial Resistance International Working Group in Cystic Fibrosis</creatorcontrib><creatorcontrib>Antimicrobial Resistance International Working Group in Cystic Fibrosis</creatorcontrib><title>Reconciling Antimicrobial Susceptibility Testing and Clinical Response in Antimicrobial Treatment of Chronic Cystic Fibrosis Lung Infections</title><title>Clinical infectious diseases</title><addtitle>Clin Infect Dis</addtitle><description>Median cystic fibrosis (CF) survival has increased dramatically over time due to several factors, including greater availability and use of antimicrobial therapies. During the progression of CF lung disease, however, the emergence of multidrug antimicrobial resistance can limit treatment effectiveness, threatening patient longevity. Current planktonic-based antimicrobial susceptibility testing lacks the ability to predict clinical response to antimicrobial treatment of chronic CF lung infections. There are numerous reasons for these limitations including bacterial phenotypic and genotypic diversity, polymicrobial interactions, and impaired antibiotic efficacy within the CF lung environment. The parallels to other chronic diseases such as non-CF bronchiectasis are discussed as well as research priorities for moving forward.</description><issn>1058-4838</issn><issn>1537-6591</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNpdkEFLAzEQhYMoVqsXf4DkLKwmJptNjmWxWigItZ6XJDvRSDe7bNJD_Q3-aFOqHjwMM_C-9xgeQleU3FKi2J31bZ5PJvgROqMlqwpRKnqcb1LKgksmJ-g8xg9CKJWkPEUTlhUhBDlDXyuwfbB-48MbnoXkO2_H3ni9wS_baGFI3mQx7fAaYtpDOrS4zri3mVlBHPoQAfvwz70eQacOQsK9w_X72GcDrnc5w-K5N2MffcTLbQ5cBAc2-RxzgU6c3kS4_NlT9Dp_WNdPxfL5cVHPloVl9ywVmpWGK6IrrmQFhknFtS4FqawUutWVkg4cVIQCJa6VTlTGSMs4V8pqqSmboptDbn42xhFcM4y-0-OuoaTZV9rkSptDpRm-PsDD1nTQ_qG_HbJvAD12ig</recordid><startdate>20191030</startdate><enddate>20191030</enddate><creator>Waters, Valerie J</creator><creator>Kidd, Timothy J</creator><creator>Canton, Rafael</creator><creator>Ekkelenkamp, Miquel B</creator><creator>Johansen, Helle Krogh</creator><creator>LiPuma, John J</creator><creator>Bell, Scott C</creator><creator>Elborn, J Stuart</creator><creator>Flume, Patrick A</creator><creator>VanDevanter, Donald R</creator><creator>Gilligan, Peter</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20191030</creationdate><title>Reconciling Antimicrobial Susceptibility Testing and Clinical Response in Antimicrobial Treatment of Chronic Cystic Fibrosis Lung Infections</title><author>Waters, Valerie J ; Kidd, Timothy J ; Canton, Rafael ; Ekkelenkamp, Miquel B ; Johansen, Helle Krogh ; LiPuma, John J ; Bell, Scott C ; Elborn, J Stuart ; Flume, Patrick A ; VanDevanter, Donald R ; Gilligan, Peter</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c323t-a35b490a74987eb3894aa5607c86ada798fefe701e10fd8f67bb8c34499ca8a13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Waters, Valerie J</creatorcontrib><creatorcontrib>Kidd, Timothy J</creatorcontrib><creatorcontrib>Canton, Rafael</creatorcontrib><creatorcontrib>Ekkelenkamp, Miquel B</creatorcontrib><creatorcontrib>Johansen, Helle Krogh</creatorcontrib><creatorcontrib>LiPuma, John J</creatorcontrib><creatorcontrib>Bell, Scott C</creatorcontrib><creatorcontrib>Elborn, J Stuart</creatorcontrib><creatorcontrib>Flume, Patrick A</creatorcontrib><creatorcontrib>VanDevanter, Donald R</creatorcontrib><creatorcontrib>Gilligan, Peter</creatorcontrib><creatorcontrib>Antimicrobial Resistance International Working Group in Cystic Fibrosis</creatorcontrib><creatorcontrib>Antimicrobial Resistance International Working Group in Cystic Fibrosis</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Clinical infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Waters, Valerie J</au><au>Kidd, Timothy J</au><au>Canton, Rafael</au><au>Ekkelenkamp, Miquel B</au><au>Johansen, Helle Krogh</au><au>LiPuma, John J</au><au>Bell, Scott C</au><au>Elborn, J Stuart</au><au>Flume, Patrick A</au><au>VanDevanter, Donald R</au><au>Gilligan, Peter</au><aucorp>Antimicrobial Resistance International Working Group in Cystic Fibrosis</aucorp><aucorp>Antimicrobial Resistance International Working Group in Cystic Fibrosis</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Reconciling Antimicrobial Susceptibility Testing and Clinical Response in Antimicrobial Treatment of Chronic Cystic Fibrosis Lung Infections</atitle><jtitle>Clinical infectious diseases</jtitle><addtitle>Clin Infect Dis</addtitle><date>2019-10-30</date><risdate>2019</risdate><volume>69</volume><issue>10</issue><spage>1812</spage><epage>1816</epage><pages>1812-1816</pages><issn>1058-4838</issn><eissn>1537-6591</eissn><abstract>Median cystic fibrosis (CF) survival has increased dramatically over time due to several factors, including greater availability and use of antimicrobial therapies. During the progression of CF lung disease, however, the emergence of multidrug antimicrobial resistance can limit treatment effectiveness, threatening patient longevity. Current planktonic-based antimicrobial susceptibility testing lacks the ability to predict clinical response to antimicrobial treatment of chronic CF lung infections. There are numerous reasons for these limitations including bacterial phenotypic and genotypic diversity, polymicrobial interactions, and impaired antibiotic efficacy within the CF lung environment. The parallels to other chronic diseases such as non-CF bronchiectasis are discussed as well as research priorities for moving forward.</abstract><cop>United States</cop><pmid>31056660</pmid><doi>10.1093/cid/ciz364</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1058-4838
ispartof Clinical infectious diseases, 2019-10, Vol.69 (10), p.1812-1816
issn 1058-4838
1537-6591
language eng
recordid cdi_crossref_primary_10_1093_cid_ciz364
source Oxford Journals Online
title Reconciling Antimicrobial Susceptibility Testing and Clinical Response in Antimicrobial Treatment of Chronic Cystic Fibrosis Lung Infections
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T13%3A51%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Reconciling%20Antimicrobial%20Susceptibility%20Testing%20and%20Clinical%20Response%20in%20Antimicrobial%20Treatment%20of%20Chronic%20Cystic%20Fibrosis%20Lung%20Infections&rft.jtitle=Clinical%20infectious%20diseases&rft.au=Waters,%20Valerie%20J&rft.aucorp=Antimicrobial%20Resistance%20International%20Working%20Group%20in%20Cystic%20Fibrosis&rft.date=2019-10-30&rft.volume=69&rft.issue=10&rft.spage=1812&rft.epage=1816&rft.pages=1812-1816&rft.issn=1058-4838&rft.eissn=1537-6591&rft_id=info:doi/10.1093/cid/ciz364&rft_dat=%3Cpubmed_cross%3E31056660%3C/pubmed_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c323t-a35b490a74987eb3894aa5607c86ada798fefe701e10fd8f67bb8c34499ca8a13%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/31056660&rfr_iscdi=true